Skip to content

eFFECTOR Therapeutics, Inc.

CIK 0001828522

← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 Apr 2024
Net Income (TTM)
−$35.52M
−58.0% YoY Q1 Apr 2024
EPS Diluted (TTM)
−$8.42
−19.0% YoY Q1 Apr 2024
Gross Margin
—
Q1 Apr 2024
Operating Margin
—
Q1 Apr 2024
Net Margin
—
Q1 Apr 2024
Free Cash Flow (TTM)
−$26.51M
Q1 Apr 2024
Cash
$15.51M
Q1 Apr 2024
Total Debt
$18.57M
Q1 Apr 2024
Shares Outstanding
4.7M sh
Q1 Apr 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings